Cargando…
Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) has a poor 5-year survival rate of 5%. Biomarkers for the early detection of pancreatic cancer are urgently needed. Transforming growth factor-beta1 (TGF-β1) is elevated in the tissues and plasma of patients with PDAC. However, no studies systemically report p...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação Brasileira de Divulgação Científica
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964897/ https://www.ncbi.nlm.nih.gov/pubmed/27464025 http://dx.doi.org/10.1590/1414-431X20165485 |
_version_ | 1782445176218714112 |
---|---|
author | Zhao, J. Liang, Y. Yin, Q. Liu, S. Wang, Q. Tang, Y. Cao, C. |
author_facet | Zhao, J. Liang, Y. Yin, Q. Liu, S. Wang, Q. Tang, Y. Cao, C. |
author_sort | Zhao, J. |
collection | PubMed |
description | Pancreatic ductal adenocarcinoma (PDAC) has a poor 5-year survival rate of 5%. Biomarkers for the early detection of pancreatic cancer are urgently needed. Transforming growth factor-beta1 (TGF-β1) is elevated in the tissues and plasma of patients with PDAC. However, no studies systemically report prognostic significance of plasma TGF-β1 levels in PDAC. In the present study, we assessed the prognostic significance of serum TGF-β levels in patients with PDAC. TGF-β levels were determined in serum from 146 PDAC patients, and 58 patients with benign pancreatic conditions. Regression models were used to correlate TGF-β levels to gender, age, stage, class, and metastasis. Survival analyses were performed using multivariate Cox models. Serum levels of TGF-β1 distinguished PDAC from benign pancreatic conditions (P<0.001) and healthy control subjects (P<0.001). Serum levels of TGF-β also distinguished tumor stage (P=0.002) and lymph node metastasis (P=0.001). High serum levels of TGF-β1 were significantly correlated with reduced patient survival. Multivariate analysis revealed that TGF-β1, lymph node metastasis and tumor stage were independent factors for PDAC survival. Our results indicate that serum TGF-β1 may be used as a potential prognostic marker for PDAC. |
format | Online Article Text |
id | pubmed-4964897 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Associação Brasileira de Divulgação Científica |
record_format | MEDLINE/PubMed |
spelling | pubmed-49648972016-08-10 Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma Zhao, J. Liang, Y. Yin, Q. Liu, S. Wang, Q. Tang, Y. Cao, C. Braz J Med Biol Res Clinical Investigation Pancreatic ductal adenocarcinoma (PDAC) has a poor 5-year survival rate of 5%. Biomarkers for the early detection of pancreatic cancer are urgently needed. Transforming growth factor-beta1 (TGF-β1) is elevated in the tissues and plasma of patients with PDAC. However, no studies systemically report prognostic significance of plasma TGF-β1 levels in PDAC. In the present study, we assessed the prognostic significance of serum TGF-β levels in patients with PDAC. TGF-β levels were determined in serum from 146 PDAC patients, and 58 patients with benign pancreatic conditions. Regression models were used to correlate TGF-β levels to gender, age, stage, class, and metastasis. Survival analyses were performed using multivariate Cox models. Serum levels of TGF-β1 distinguished PDAC from benign pancreatic conditions (P<0.001) and healthy control subjects (P<0.001). Serum levels of TGF-β also distinguished tumor stage (P=0.002) and lymph node metastasis (P=0.001). High serum levels of TGF-β1 were significantly correlated with reduced patient survival. Multivariate analysis revealed that TGF-β1, lymph node metastasis and tumor stage were independent factors for PDAC survival. Our results indicate that serum TGF-β1 may be used as a potential prognostic marker for PDAC. Associação Brasileira de Divulgação Científica 2016-07-25 /pmc/articles/PMC4964897/ /pubmed/27464025 http://dx.doi.org/10.1590/1414-431X20165485 Text en http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License |
spellingShingle | Clinical Investigation Zhao, J. Liang, Y. Yin, Q. Liu, S. Wang, Q. Tang, Y. Cao, C. Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma |
title | Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma |
title_full | Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma |
title_fullStr | Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma |
title_full_unstemmed | Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma |
title_short | Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma |
title_sort | clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma |
topic | Clinical Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964897/ https://www.ncbi.nlm.nih.gov/pubmed/27464025 http://dx.doi.org/10.1590/1414-431X20165485 |
work_keys_str_mv | AT zhaoj clinicalandprognosticsignificanceofserumtransforminggrowthfactorbeta1levelsinpatientswithpancreaticductaladenocarcinoma AT liangy clinicalandprognosticsignificanceofserumtransforminggrowthfactorbeta1levelsinpatientswithpancreaticductaladenocarcinoma AT yinq clinicalandprognosticsignificanceofserumtransforminggrowthfactorbeta1levelsinpatientswithpancreaticductaladenocarcinoma AT lius clinicalandprognosticsignificanceofserumtransforminggrowthfactorbeta1levelsinpatientswithpancreaticductaladenocarcinoma AT wangq clinicalandprognosticsignificanceofserumtransforminggrowthfactorbeta1levelsinpatientswithpancreaticductaladenocarcinoma AT tangy clinicalandprognosticsignificanceofserumtransforminggrowthfactorbeta1levelsinpatientswithpancreaticductaladenocarcinoma AT caoc clinicalandprognosticsignificanceofserumtransforminggrowthfactorbeta1levelsinpatientswithpancreaticductaladenocarcinoma |